Urokinase for Injection

Urokinase for Injection Market Outlook

The global Urokinase for Injection market is projected to reach approximately USD 1.2 billion by 2035, growing at a CAGR of around 5.8% during the forecast period from 2025 to 2035. This growth is primarily attributed to the rising incidence of thrombolytic disorders, an increasing geriatric population susceptible to cardiovascular ailments, and advancements in biotechnology that have enhanced the production of urokinase. Additionally, the growing awareness about the benefits of thrombolytic therapy in treating conditions like acute myocardial infarction and pulmonary embolism is expected to further boost market demand. As healthcare systems around the world evolve, there is a notable shift towards minimally invasive procedures, which are often facilitated by urokinase, thus propelling market growth. Moreover, the introduction of innovative formulations and delivery mechanisms will also contribute to the market’s expansion.

Growth Factor of the Market

The Urokinase for Injection market is experiencing substantial growth due to several pivotal factors. First, the increasing prevalence of thromboembolic conditions, such as deep vein thrombosis (DVT) and pulmonary embolism (PE), has necessitated effective treatment options, leading to higher demand for urokinase. Secondly, the shift towards advanced therapeutic approaches in emergency medicine, particularly in acute myocardial infarction treatment, is driving market expansion. Furthermore, the development of biosimilars and the enhancement in recombinant technology have increased the availability and affordability of urokinase products, making them more accessible to healthcare providers. Additionally, ongoing research and clinical trials aimed at discovering new applications for urokinase in various medical scenarios will continue to stimulate market growth. Lastly, an increase in government funding and initiatives focused on improving healthcare infrastructure is expected to further bolster the market.

Key Highlights of the Market

• The global Urokinase for Injection market is expected to reach USD 1.2 billion by 2035.
• Projected CAGR of around 5.8% from 2025 to 2035.
• Growing prevalence of thromboembolic disorders significantly impacts market demand.
• Advancements in biotechnology and production processes are enhancing product availability.
• Increasing healthcare funding and infrastructure development will support growth.

By Product Type

High Purity Urokinase:

High Purity Urokinase is a prominent segment within the Urokinase for Injection market, characterized by its superior efficacy and lower risk of adverse reactions. This type is formulated to eliminate impurities, resulting in a product that is more effective in thrombolysis and hence preferred in critical care settings. The high purity levels allow for greater safety margins, making it suitable for use in patients with complex medical histories. This segment is gaining traction due to increased demand from hospitals and healthcare professionals seeking safe and effective thrombolytic agents. Furthermore, ongoing advancements in purification techniques are expected to enhance the production of high purity urokinase, thereby driving its market share upwards.

Low Purity Urokinase:

Low Purity Urokinase serves as a cost-effective alternative to high purity formulations and finds utility in various therapeutic settings. Although it may not offer the same level of efficacy, many healthcare practitioners still utilize low purity versions due to their affordability. This segment caters primarily to resource-constrained healthcare systems where financial considerations are critical. The continued use of low purity urokinase is supported by its ability to treat a wide range of thrombolytic conditions, albeit with a higher risk of side effects. Thus, while the growth of this segment may be slower compared to its high purity counterpart, it remains an essential part of the market, particularly in developing regions.

Recombinant Urokinase:

Recombinant Urokinase has emerged as a significant player in the Urokinase for Injection market, driven by its ability to offer a more consistent and reliable therapeutic profile. Produced through genetic engineering techniques, recombinant urokinase provides a more controlled product with fewer impurities. This has made it particularly appealing for clinical applications in critical care settings. The growth of this segment is further supported by ongoing research focused on expanding the applications of recombinant urokinase in various cardiovascular treatments. As the technology for recombinant product development evolves, we expect this segment to capture a larger market share due to its innovative nature.

Natural Urokinase:

Natural Urokinase, derived from human or animal sources, is a traditional form of thrombolytic agent that has been used for many years. Although its popularity has waned with the advent of recombinant and high-purity formulations, it still holds relevance in specific therapeutic applications. This segment is favored for its historical efficacy and is often used in niche markets where traditional therapies are preferred. Additionally, the natural variant tends to have a more established safety profile, which appeals to some clinicians. As such, it continues to hold a modest share of the Urokinase market, particularly in regions where access to newer formulations is limited.

Biosimilar Urokinase:

Biosimilar Urokinase has emerged as a crucial segment in the market, particularly due to the growing demand for cost-effective therapeutic options. As patents on various biologics expire, biosimilars offer a competitive edge by providing similar efficacy at lower costs. The biosimilars market is driven by increased healthcare spending and the need for affordable healthcare solutions globally. Furthermore, the regulatory frameworks surrounding biosimilars are evolving, which enhances confidence among healthcare providers regarding their safety and efficacy. As awareness about biosimilar products increases, we can expect substantial growth in this segment of the Urokinase for Injection market.

By Application

Acute Myocardial Infarction:

Acute myocardial infarction (AMI) is one of the leading applications of Urokinase for Injection, as it plays a critical role in thrombolytic therapy. The rapid administration of urokinase can significantly dissolve blood clots that block coronary arteries, restoring blood flow and minimizing heart damage. The increasing incidence of AMI, largely attributed to lifestyle factors such as poor diet and physical inactivity, is propelling the demand for effective thrombolytic agents, including urokinase. Additionally, the growing awareness among healthcare providers regarding the efficacy of urokinase in emergency medicine is anticipated to further stimulate market growth in this application.

Pulmonary Embolism:

Pulmonary embolism (PE) is another vital application area for Urokinase for Injection, as it has been shown to rapidly dissolve clots obstructing pulmonary arteries. The treatment of PE is critical, given its potentially life-threatening nature, and urokinase’s effectiveness makes it a preferred choice in acute care settings. With a rising number of cases attributed to various risk factors, including prolonged immobility and certain medical conditions, the demand for urokinase in this segment is expected to grow. Furthermore, advancements in diagnostic technologies are enhancing early detection rates, which could result in increased usage of urokinase in treating PE.

Deep Vein Thrombosis:

Deep vein thrombosis (DVT) represents a significant application for Urokinase for Injection, as it is crucial in treating clots that form in deep veins, usually in the legs. The increasing prevalence of DVT, particularly among aging populations and those with sedentary lifestyles, has heightened the demand for effective therapeutic options. Urokinase's ability to rapidly dissolve these clots makes it an essential tool in clinical settings. Additionally, as awareness regarding the risks associated with DVT continues to rise, healthcare providers are more inclined to utilize urokinase for its proven efficacy, thus contributing to the segment's growth.

Stroke:

Stroke management is another critical application area for Urokinase for Injection, especially in the context of ischemic strokes, where blood clots obstruct blood flow to the brain. Quick and effective thrombolytic therapy is essential for improving outcomes in stroke patients, and urokinase has been recognized for its effectiveness in such scenarios. The increasing incidence of strokes, driven by factors such as hypertension and diabetes, is spurring the demand for urokinase as a treatment option. Furthermore, as clinical guidelines evolve to emphasize timely thrombolysis, the role of urokinase in acute stroke management is becoming increasingly significant.

Peripheral Vascular Thrombosis:

Peripheral vascular thrombosis is a notable application for Urokinase for Injection, particularly in treating blood clots that form in the peripheral veins. This condition can lead to severe complications if not treated promptly, making effective thrombolytic therapy crucial. Urokinase is utilized to dissolve these clots and restore blood flow, providing significant relief for patients. The rising awareness about peripheral vascular diseases and the increasing number of patients seeking treatment are anticipated to drive market growth in this application segment. Moreover, ongoing research into the efficacy of urokinase in treating various aspects of peripheral vascular disease will likely expand its application range.

By Distribution Channel

Hospitals:

Hospitals serve as the primary distribution channel for Urokinase for Injection, given that they are equipped to handle emergency situations requiring thrombolytic therapy. With dedicated emergency departments and specialized care units, hospitals account for a substantial portion of urokinase sales, particularly in critical care scenarios such as acute myocardial infarction and pulmonary embolism. The availability of skilled healthcare professionals and advanced medical technologies further enhances the use of urokinase in hospitals. Moreover, as hospitals continue to expand their cardiac care programs, we expect to see further growth in the demand for urokinase.

Retail Pharmacies:

Retail pharmacies represent an important distribution channel for Urokinase, particularly for patients requiring long-term management of thromboembolic conditions. While less commonly used for acute emergencies, urokinase can still be prescribed for outpatient use, and retail pharmacies play a pivotal role in making it accessible to patients. The convenience offered by retail pharmacies, combined with their ability to provide consultation and medication management, supports the ongoing demand for urokinase. As awareness regarding thrombotic conditions grows, we anticipate an uptick in prescriptions filled through retail channels.

Online Pharmacies:

Online pharmacies are becoming increasingly popular as a distribution channel for Urokinase for Injection, particularly in the context of the growing trend toward e-commerce in healthcare. Patients appreciate the convenience and anonymity of purchasing medications online, especially for sensitive health issues like thromboembolic disorders. Additionally, the ongoing COVID-19 pandemic has accelerated the adoption of online pharmacies as patients seek to minimize in-person visits. As regulations regarding the sale of prescription medications online continue to evolve, the market for Urokinase through online channels is expected to expand significantly.

Drug Stores:

Drug stores also play a significant role in the distribution of Urokinase, particularly in local communities where access to hospitals and larger pharmacies may be limited. These establishments often serve as the first point of contact for patients seeking medication for thromboembolic conditions. With pharmacists being key players in educating patients about their conditions and treatment options, drug stores contribute to the awareness and use of Urokinase for Injection. As the demand for accessible healthcare solutions increases, drug stores are likely to see a growth in sales of urokinase products.

By Ingredient Type

Animal-derived Urokinase:

Animal-derived Urokinase remains a relevant segment within the market, particularly for its historical significance and established efficacy in thrombolytic therapy. Extracted from animal tissues, this type of urokinase has been used for decades to treat various thromboembolic disorders. While newer formulations may be gaining traction, animal-derived urokinase is still favored in specific scenarios due to its proven track record. The market for this ingredient type is expected to remain stable, particularly in regions where access to advanced treatments is limited or where traditional therapies are preferred.

Human-derived Urokinase:

Human-derived Urokinase is another essential ingredient type, prized for its efficacy in clinical applications. Derived from human sources, this type is commonly utilized in thrombolytic therapy due to its compatibility with the human body. This segment is important for its historical use and clinical validation in treating conditions such as acute myocardial infarction and pulmonary embolism. Given the growing emphasis on personalized medicine and the increasing focus on patient safety, the demand for human-derived urokinase is expected to persist, particularly in specialized medical facilities.

Genetically Modified Organisms-derived Urokinase:

Genetically modified organisms (GMO)-derived Urokinase has gained significance in recent years due to the advancements in biotechnology. This ingredient type leverages genetic engineering techniques to produce urokinase that is consistent in quality and efficacy. By utilizing recombinant DNA technology, manufacturers can yield large quantities of urokinase while maintaining high purity levels. The growth of this segment is expected to be robust, driven by ongoing research aimed at expanding the applications of genetically modified urokinase in various therapeutic areas. As healthcare providers increasingly recognize the benefits of GMOs in medicine, the market for this ingredient type will likely grow.

Plant-derived Urokinase:

Plant-derived Urokinase is an innovative segment that has emerged as researchers explore alternative sources for thrombolytic agents. Although still in the early stages of development compared to other ingredient types, there is significant interest in harnessing plant-based compounds for medical applications. The potential for fewer side effects and enhanced safety profiles makes plant-derived urokinase an attractive option for future research and development. As the pharmaceutical industry increasingly focuses on bio-based solutions, we may see a gradual rise in the interest and investment in plant-derived urokinase products.

Synthetic Urokinase:

Synthetic Urokinase is another innovative ingredient type that holds promise within the Urokinase for Injection market. Developed through chemical synthesis, this form of urokinase can offer higher specificity and potentially fewer adverse effects. The ongoing research into synthetic alternatives is likely to yield exciting developments, especially as the industry pushes towards personalized medicine and tailored therapeutic options. While synthetic urokinase is currently a smaller segment, its potential benefits may lead to increased attention and investment, driving future growth in this area.

By Region

The regional analysis of the Urokinase for Injection market reveals significant growth opportunities across various regions. North America holds a dominant position, capturing approximately 40% of the global market share in 2025, primarily due to the advanced healthcare infrastructure, high prevalence of thromboembolic disorders, and increased research activities. The region is projected to grow at a CAGR of around 6.2%, driven by rising demand for innovative therapeutic options and increasing healthcare expenditures. Furthermore, the presence of key market players and ongoing clinical trials enhances the growth prospects for the Urokinase market in North America.

In Europe, the Urokinase for Injection market is also witnessing robust growth, accounting for approximately 30% of the global market share. The region benefits from a well-established healthcare system and increasing awareness about thrombolytic therapies. The European market is expected to grow at a CAGR of 5.5% through 2035, fueled by advancements in medical technology and the rising incidence of cardiovascular diseases. In the Asia Pacific region, market growth is driven by the increasing geriatric population and improving healthcare access, with an expected CAGR of 5.4%. Additionally, Latin America and the Middle East & Africa are gradually adapting to thrombolytic therapies, indicating potential growth in these regions as awareness and healthcare infrastructure improve.

Opportunities

The Urokinase for Injection market presents numerous opportunities driven by the growing global burden of thromboembolic disorders. As awareness regarding the importance of swift thrombolytic therapy increases, healthcare providers are increasingly adopting urokinase as a viable treatment option. This trend is particularly notable in emerging markets where healthcare access is improving, leading to higher diagnosis and treatment rates for conditions such as acute myocardial infarction and pulmonary embolism. Moreover, the rise of telemedicine has enabled healthcare professionals to diagnose and treat patients remotely, further increasing opportunities for urokinase administration in outpatient settings. The emphasis on developing cost-effective therapies, such as biosimilars, is also creating opportunities for market players to introduce innovative products that cater to the budget-conscious segments of healthcare.

Another significant opportunity lies in the advancement of biotechnology and product development. Ongoing research into new formulations, delivery mechanisms, and applications of urokinase is likely to yield breakthroughs that can significantly enhance patient outcomes. Additionally, collaboration between pharmaceutical companies and research institutions can facilitate rapid advancements in urokinase applications, such as its use in managing chronic thromboembolic pulmonary hypertension. By investing in research and development, companies can position themselves as leaders in this competitive landscape and capture larger market shares, thereby driving overall market growth.

Threats

Despite the positive outlook for the Urokinase for Injection market, certain threats could impede growth. One major threat stems from the increasing competition from alternative thrombolytic agents and newer therapies. As the medical community explores innovative solutions, such as mechanical thrombectomy and other non-pharmacological therapies, there may be a shift away from traditional thrombolytic treatments like urokinase. This could adversely affect market demand and revenue for urokinase products, especially if emerging therapies demonstrate superior efficacy or safety profiles. Additionally, regulatory hurdles and stringent approval processes for new formulations can slow down the introduction of innovative products, limiting market dynamism and growth.

Another concerning trend is the rising cost of healthcare and the associated pressure on pharmaceutical companies to lower prices. As countries strive to implement cost containment measures, the pressure to reduce the prices of therapeutic agents like urokinase could impact profit margins for manufacturers. Moreover, the potential for litigation related to side effects or complications arising from thrombolytic therapy could pose operational and financial challenges for companies in this space, thereby restraining market growth. Companies will need to navigate these threats effectively to ensure sustainability and profitability in the competitive landscape.

Competitor Outlook

• Roche
• Genentech
• Bristol-Myers Squibb
• Amgen
• Sandoz
• Teva Pharmaceuticals
• Hualan Biological Engineering Inc.
• Shanghai RAAS Blood Products Co., Ltd.
• UCB S.A.
• Pfizer Inc.
• Abbott Laboratories
• Merck & Co., Inc.
• CSL Behring
• Grifols S.A.
• Biocon Ltd.

The competitive landscape of the Urokinase for Injection market is characterized by a mix of established pharmaceutical giants and emerging biotechnology firms. Major companies, such as Roche and Genentech, have significant market shares due to their extensive product portfolios and strong research capabilities. These companies invest heavily in clinical trials and product innovation, ensuring that they remain at the forefront of therapeutic advancements. Their established distribution networks and strategic collaborations with healthcare providers further bolster their competitive positions. Additionally, their commitment to quality and safety provides a distinct advantage in the market, where trust and reliability are paramount.

Emerging players like Biocon Ltd. and Hualan Biological Engineering Inc. are making strides in the Urokinase market by focusing on biosimilars and innovative formulations. These companies leverage advancements in biotechnology to create cost-effective alternatives, thereby capturing market segments that prioritize affordability. Their agility and focus on niche markets allow them to respond quickly to changing healthcare trends while catering to specific patient needs. As these players continue to innovate and expand their offerings, they pose a competitive challenge to established companies, potentially reshaping the market landscape.

Looking ahead, the Urokinase for Injection market will likely experience increased consolidation as companies seek to enhance their capabilities through mergers and acquisitions. Collaboration among firms can lead to synergies that improve product development timelines and expand market reach. Additionally, partnerships with research institutions can facilitate the discovery of new applications for urokinase, driving further growth. Overall, the competitive landscape will remain dynamic, with ongoing innovations and strategic maneuvers shaping the future of the Urokinase market.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Roche
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Sandoz
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 UCB S.A.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Genentech
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Biocon Ltd.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 CSL Behring
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Pfizer Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Grifols S.A.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Merck & Co., Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Abbott Laboratories
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Bristol-Myers Squibb
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Teva Pharmaceuticals
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Hualan Biological Engineering Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Shanghai RAAS Blood Products Co., Ltd.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Urokinase for Injection Market, By Application
    • 6.1.1 Acute Myocardial Infarction
    • 6.1.2 Pulmonary Embolism
    • 6.1.3 Deep Vein Thrombosis
    • 6.1.4 Stroke
    • 6.1.5 Peripheral Vascular Thrombosis
  • 6.2 Urokinase for Injection Market, By Product Type
    • 6.2.1 High Purity Urokinase
    • 6.2.2 Low Purity Urokinase
    • 6.2.3 Recombinant Urokinase
    • 6.2.4 Natural Urokinase
    • 6.2.5 Biosimilar Urokinase
  • 6.3 Urokinase for Injection Market, By Ingredient Type
    • 6.3.1 Animal-derived Urokinase
    • 6.3.2 Human-derived Urokinase
    • 6.3.3 Genetically Modified Organisms-derived Urokinase
    • 6.3.4 Plant-derived Urokinase
    • 6.3.5 Synthetic Urokinase
  • 6.4 Urokinase for Injection Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies
    • 6.4.4 Drug Stores

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Urokinase for Injection Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Urokinase for Injection market is categorized based on

By Product Type

• High Purity Urokinase
• Low Purity Urokinase
• Recombinant Urokinase
• Natural Urokinase
• Biosimilar Urokinase

By Application

• Acute Myocardial Infarction
• Pulmonary Embolism
• Deep Vein Thrombosis
• Stroke
• Peripheral Vascular Thrombosis

By Distribution Channel

• Hospitals
• Retail Pharmacies
• Online Pharmacies
• Drug Stores

By Ingredient Type

• Animal-derived Urokinase
• Human-derived Urokinase
• Genetically Modified Organisms-derived Urokinase
• Plant-derived Urokinase
• Synthetic Urokinase

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Roche
• Genentech
• Bristol-Myers Squibb
• Amgen
• Sandoz
• Teva Pharmaceuticals
• Hualan Biological Engineering Inc.
• Shanghai RAAS Blood Products Co., Ltd.
• UCB S.A.
• Pfizer Inc.
• Abbott Laboratories
• Merck & Co., Inc.
• CSL Behring
• Grifols S.A.
• Biocon Ltd.